DiscoverCME in Minutes: Education in Rheumatology, Immunology, & Infectious DiseasesHussein Tawbi, MD, PhD - Evolving Melanoma Care: The Clinical Impact of Anti-LAG-3/PD-1 Combinations
Hussein Tawbi, MD, PhD - Evolving Melanoma Care: The Clinical Impact of Anti-LAG-3/PD-1 Combinations

Hussein Tawbi, MD, PhD - Evolving Melanoma Care: The Clinical Impact of Anti-LAG-3/PD-1 Combinations

Update: 2025-07-07
Share

Description

Please visit answersincme.com/XWB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in melanoma discusses combination anti–programmed cell death protein 1 (PD-1) plus anti–lymphocyte-activation gene 3 (LAG-3) therapy. Upon completion of this activity, participants should be better able to: Review the latest clinical evidence supporting use of combination anti–PD-1 plus anti-LAG-3 therapy in the first-line setting for patients with unresectable, advanced melanoma; Identify eligible patients with unresectable, advanced melanoma who can benefit from the use of combination anti–PD-1 plus anti–LAG-3 therapy in the first-line setting; and Outline strategies for managing adverse events associated with combination anti–PD-1 plus anti–LAG-3 therapy.
Comments 
In Channel
loading
00:00
00:00
1.0x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Hussein Tawbi, MD, PhD - Evolving Melanoma Care: The Clinical Impact of Anti-LAG-3/PD-1 Combinations

Hussein Tawbi, MD, PhD - Evolving Melanoma Care: The Clinical Impact of Anti-LAG-3/PD-1 Combinations

Answers in CME